ES2180564T3 - 2-fenil-3-azoilbenzotiofenos para aumentar la expresion de trombomodulina. - Google Patents
2-fenil-3-azoilbenzotiofenos para aumentar la expresion de trombomodulina.Info
- Publication number
- ES2180564T3 ES2180564T3 ES94309485T ES94309485T ES2180564T3 ES 2180564 T3 ES2180564 T3 ES 2180564T3 ES 94309485 T ES94309485 T ES 94309485T ES 94309485 T ES94309485 T ES 94309485T ES 2180564 T3 ES2180564 T3 ES 2180564T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- formula
- phenyl
- azoilbenzotiofenos
- thrombomodulin expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Seasonings (AREA)
Abstract
UN METODO PARA INCREMENTAR LA EXPRESION TROMBOMODULINA COMPRENDIENDO ADMINISTRAR A UN HUMANO EN LA NECESIDAD DE TRATAMIENTO UNA CANTIDAD EFECTIVA DE UN COMPONENTE QUE TIENE LA FORMULA (I) EN DONDE EN DONDE R1 Y R3 SON INDEPENDIENTEMENTE HIDROGENO, -CH3, (ALQUILO C1-C6)-CO O CO-AR, EN DONDE AR ES FENILO OPCIONALMENTE SUSTITUIDO; R2 ES SELECCIONADO DEL GRUPO QUE CONSTA DE PIRROLIDINA, HEXAMETILENEIMINO, Y PIPERIDINO; O UNA SAL ACEPTABLE FARMACEUTICAMENTE DE SU SOLVENTE. TAMBIEN ABARCA LA INVENCION UN METODO PARA INHIBIR UNA ENFERMEDAD TROMBOTICA O SUCESO QUE INCLUYA ADMINISTRAR A UN HUMANO EN LA NECESIDAD DE ELLO UNA CANTIDAD EFECTIVA DE UN COMPONENTE DE LA FORMULA 1. TAMBIEN ABARCA LA INVENCION UN METODO PARA INCREMENTAR LA PROPORCION DE ACTIVACION DE LA PROTEINA C QUE INCLUYE LA ADMINISTRACION DE UN COMPONENTE DE LA FORMULA 1.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/170,944 US5476862A (en) | 1993-12-21 | 1993-12-21 | Methods of increasing thrombomodulin expression |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2180564T3 true ES2180564T3 (es) | 2003-02-16 |
Family
ID=22621914
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES94309485T Expired - Lifetime ES2180564T3 (es) | 1993-12-21 | 1994-12-19 | 2-fenil-3-azoilbenzotiofenos para aumentar la expresion de trombomodulina. |
Country Status (22)
Country | Link |
---|---|
US (2) | US5476862A (es) |
EP (1) | EP0659427B1 (es) |
JP (1) | JPH07196496A (es) |
KR (1) | KR950016727A (es) |
CN (1) | CN1044679C (es) |
AT (1) | ATE220904T1 (es) |
AU (1) | AU692194B2 (es) |
CA (1) | CA2138490A1 (es) |
CZ (1) | CZ288983B6 (es) |
DE (1) | DE69431035T2 (es) |
DK (1) | DK0659427T3 (es) |
ES (1) | ES2180564T3 (es) |
HU (1) | HUT71470A (es) |
IL (1) | IL112036A (es) |
NO (1) | NO310596B1 (es) |
NZ (1) | NZ270169A (es) |
PH (1) | PH31325A (es) |
PT (1) | PT659427E (es) |
RU (2) | RU2190405C2 (es) |
TW (1) | TW273509B (es) |
UA (1) | UA27910C2 (es) |
ZA (1) | ZA9410079B (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5492927A (en) * | 1993-12-21 | 1996-02-20 | Eli Lilly And Company | Non-peptide tachykinin receptor antagonists to treat allergy |
US6562862B1 (en) | 1994-10-20 | 2003-05-13 | Eli Lilly And Company | Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y |
US5484808A (en) * | 1995-02-09 | 1996-01-16 | Eli Lilly And Company | Methods of inhibiting cell-cell adhesion |
US5843974A (en) * | 1995-06-06 | 1998-12-01 | Eli Lilly And Company | Methods of inhibiting melanoma using Benzothiophenes as cytotoxic agents per se |
US6545027B1 (en) | 1995-06-07 | 2003-04-08 | Eli Lilly And Company | Methods of modulating NF-kB transcription factor |
EP0747051B1 (en) * | 1995-06-07 | 2002-07-24 | Eli Lilly And Company | Treatment of diseases by inducing BEF-1 transcription factor |
IL120266A (en) | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
TW442286B (en) * | 1996-02-28 | 2001-06-23 | Pfizer | New therapeutic uses of estrogen agonists |
US6025373A (en) * | 1997-04-22 | 2000-02-15 | Eli Lilly And Company | Methods for reducing fibrinogen |
US6103740A (en) * | 1997-08-21 | 2000-08-15 | Eli Lilly And Company | Methods for lowering platelet counts |
US7189703B2 (en) * | 1998-01-09 | 2007-03-13 | Intracell, Llc | Treatment and diagnosis of alzheimer's disease |
FR2777784B1 (fr) * | 1998-04-27 | 2004-03-19 | Arepa | Composition pharmaceutique a base d'estrogene et de progesterone |
US6353003B1 (en) | 1998-06-17 | 2002-03-05 | Eli Lilly And Company | Method for reducing levels of homocysteine and C-reactive protein |
ES2246234T3 (es) | 1999-05-04 | 2006-02-16 | Strakan International Limited | Glicosidos de androgenos y actividad androgenica de los mismos. |
JPWO2002028416A1 (ja) * | 2000-09-30 | 2004-02-12 | 持田製薬株式会社 | 溶血性貧血の予防・治療剤 |
US20060148695A1 (en) * | 2005-01-03 | 2006-07-06 | National Cheng Kung University | Novel angiogenic composition and use thereof |
WO2008116141A1 (en) * | 2007-03-21 | 2008-09-25 | Emisphere Technologies, Inc. | Allylqxy and alkyloxy benzoic acid delivery agents |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
US4380635A (en) * | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
US5075321A (en) * | 1987-03-24 | 1991-12-24 | University Of Pennsylvania | Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes |
JP3157882B2 (ja) * | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | 新規なベンゾチオフエン誘導体 |
WO1993010742A2 (en) * | 1991-11-27 | 1993-06-10 | Novo Nordisk A/S | Chemical compounds, their preparation and use |
-
1993
- 1993-12-21 US US08/170,944 patent/US5476862A/en not_active Expired - Fee Related
-
1994
- 1994-12-19 AU AU81554/94A patent/AU692194B2/en not_active Ceased
- 1994-12-19 CA CA002138490A patent/CA2138490A1/en not_active Abandoned
- 1994-12-19 UA UA94129188A patent/UA27910C2/uk unknown
- 1994-12-19 CN CN94119739A patent/CN1044679C/zh not_active Expired - Fee Related
- 1994-12-19 NZ NZ270169A patent/NZ270169A/en unknown
- 1994-12-19 DK DK94309485T patent/DK0659427T3/da active
- 1994-12-19 RU RU98113525/14A patent/RU2190405C2/ru not_active IP Right Cessation
- 1994-12-19 ES ES94309485T patent/ES2180564T3/es not_active Expired - Lifetime
- 1994-12-19 AT AT94309485T patent/ATE220904T1/de not_active IP Right Cessation
- 1994-12-19 JP JP6314544A patent/JPH07196496A/ja not_active Ceased
- 1994-12-19 ZA ZA9410079A patent/ZA9410079B/xx unknown
- 1994-12-19 HU HU9403664A patent/HUT71470A/hu unknown
- 1994-12-19 TW TW083111836A patent/TW273509B/zh active
- 1994-12-19 EP EP94309485A patent/EP0659427B1/en not_active Expired - Lifetime
- 1994-12-19 PH PH49577A patent/PH31325A/en unknown
- 1994-12-19 CZ CZ19943211A patent/CZ288983B6/cs not_active IP Right Cessation
- 1994-12-19 KR KR1019940034918A patent/KR950016727A/ko not_active Application Discontinuation
- 1994-12-19 NO NO19944915A patent/NO310596B1/no unknown
- 1994-12-19 RU RU94044356/14A patent/RU2125450C1/ru not_active IP Right Cessation
- 1994-12-19 DE DE69431035T patent/DE69431035T2/de not_active Expired - Fee Related
- 1994-12-19 PT PT94309485T patent/PT659427E/pt unknown
- 1994-12-19 IL IL11203694A patent/IL112036A/en not_active IP Right Cessation
-
1995
- 1995-08-21 US US08/517,517 patent/US5700815A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP0659427B1 (en) | 2002-07-24 |
DK0659427T3 (da) | 2002-09-02 |
EP0659427A1 (en) | 1995-06-28 |
DE69431035D1 (de) | 2002-08-29 |
IL112036A0 (en) | 1995-03-15 |
ATE220904T1 (de) | 2002-08-15 |
CN1044679C (zh) | 1999-08-18 |
US5700815A (en) | 1997-12-23 |
CN1108932A (zh) | 1995-09-27 |
US5476862A (en) | 1995-12-19 |
CA2138490A1 (en) | 1995-06-22 |
JPH07196496A (ja) | 1995-08-01 |
NO310596B1 (no) | 2001-07-30 |
RU2190405C2 (ru) | 2002-10-10 |
AU692194B2 (en) | 1998-06-04 |
RU94044356A (ru) | 1996-10-10 |
CZ321194A3 (en) | 1995-08-16 |
RU2125450C1 (ru) | 1999-01-27 |
NO944915L (no) | 1995-06-22 |
IL112036A (en) | 1999-01-26 |
PH31325A (en) | 1998-07-06 |
PT659427E (pt) | 2002-11-29 |
ZA9410079B (en) | 1996-06-19 |
TW273509B (en) | 1996-04-01 |
KR950016727A (ko) | 1995-07-20 |
NO944915D0 (no) | 1994-12-19 |
CZ288983B6 (cs) | 2001-10-17 |
DE69431035T2 (de) | 2003-01-30 |
HU9403664D0 (en) | 1995-02-28 |
AU8155494A (en) | 1995-06-29 |
HUT71470A (en) | 1995-11-28 |
UA27910C2 (uk) | 2000-10-16 |
NZ270169A (en) | 1997-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA9410084B (en) | Methods of inhibiting thrombin | |
ES2180564T3 (es) | 2-fenil-3-azoilbenzotiofenos para aumentar la expresion de trombomodulina. | |
ES2157957T3 (es) | Procedimientos para inhibir la endometriosis. | |
ATE150307T1 (de) | Hemmung von seborrhoe und akne | |
ES2172525T3 (es) | Inhibicion de la fibrosis uterina. | |
IL111289A0 (en) | Methods for inhibiting angiogenesis and angiogenic diseases | |
DK0652002T3 (da) | Anvendelse af 2-phenyl-3-aroylebenzothiophener til fremstilling af et medikament til hæmning af brusknedbrydning | |
MD1560G2 (ro) | Compuşi ciclici, compoziţii farmaceutice pe baza lor şi metode de tratament al infecţiilor sau bolilor provocate de retrovirusuri |